Cingulate Inc. Advances ADHD Treatment with CTx-1301, Eyes FDA Approval

Cingulate Inc. (NASDAQ: CING) has recently been in the spotlight following Stonegate Capital Partners' initiation of coverage, highlighting the company's progress with its lead ADHD asset, CTx-1301. This development is crucial as it addresses a significant gap in ADHD treatment, offering a once-daily stimulant therapy with rapid onset and sustained efficacy throughout the day, a notable improvement over current therapies that often require additional doses.

The importance of this advancement cannot be overstated, given the estimated $22 billion U.S. ADHD market. Cingulate's CTx-1301, developed using its proprietary Precision Timed Release™ (PTR™) platform, has shown promising results in Phase 3 pediatric studies, with all tested doses demonstrating statistically significant improvements on the ADHD-RS-5 scale. These findings, coupled with the positive outcomes from the high-dose food effect study, underscore the potential of CTx-1301 to enhance treatment adherence and flexibility for patients.

With the New Drug Application (NDA) submission on the horizon for mid-2025, Cingulate is poised to make a significant impact on the ADHD treatment landscape. The NDA will include comprehensive safety and efficacy data from nine clinical trials, reinforcing the drug's strong safety profile and tolerability. Approval of CTx-1301 could mark a paradigm shift in ADHD treatment, offering the first true once-daily stimulant that combines rapid onset with full-day efficacy.

However, the path to commercialization is not without challenges. Cingulate's financials reveal a net loss of $3.8 million for the first quarter of 2025, with operating cash burn totaling $4.6 million. The company's ability to secure additional financing will be critical in supporting its NDA filing, pre-launch activities, and clinical operations. Despite these hurdles, the potential of CTx-1301 to redefine ADHD treatment and capture a significant share of the market makes Cingulate a company to watch in the coming years.